Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) and Septerna (NASDAQ:SEPN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
Insider and Institutional Ownership
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Septerna shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of current ratings and target prices for Recursion Pharmaceuticals and Septerna, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Recursion Pharmaceuticals | 1 | 2 | 2 | 0 | 2.20 |
| Septerna | 1 | 1 | 8 | 1 | 2.82 |
Recursion Pharmaceuticals currently has a consensus price target of $8.18, suggesting a potential upside of 171.31%. Septerna has a consensus price target of $56.44, suggesting a potential upside of 36.44%. Given Recursion Pharmaceuticals’ higher possible upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Septerna.
Profitability
This table compares Recursion Pharmaceuticals and Septerna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Recursion Pharmaceuticals | -697.15% | -47.85% | -36.26% |
| Septerna | -61.29% | -14.98% | -10.03% |
Valuation & Earnings
This table compares Recursion Pharmaceuticals and Septerna”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Recursion Pharmaceuticals | $67.01 million | 28.02 | -$644.76 million | ($0.90) | -3.35 |
| Septerna | $96.27 million | 20.43 | -$48.88 million | ($1.29) | -32.07 |
Septerna has higher revenue and earnings than Recursion Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Recursion Pharmaceuticals has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Septerna has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500.
Summary
Septerna beats Recursion Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. is a biotechnology company that uses automation, large-scale biological and chemical data, and machine learning to discover and develop medicines. Its platform, known as Recursion OS, is designed to identify relationships between biological processes and potential treatments. The company develops drug candidates for areas including rare diseases and oncology, and it also works with pharmaceutical partners on drug discovery and development. Its research combines laboratory experiments with computational analysis to evaluate potential therapeutic targets and compounds.
About Septerna
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
